1. Home
  2. PLUG vs MYGN Comparison

PLUG vs MYGN Comparison

Compare PLUG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plug Power Inc.

PLUG

Plug Power Inc.

HOLD

Current Price

$2.44

Market Cap

2.9B

Sector

Energy

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.75

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLUG
MYGN
Founded
1997
1991
Country
United States
United States
Employees
N/A
2700
Industry
Industrial Machinery/Components
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
444.2M
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
PLUG
MYGN
Price
$2.44
$4.75
Analyst Decision
Hold
Buy
Analyst Count
12
8
Target Price
$2.12
★ $7.64
AVG Volume (30 Days)
★ 60.2M
1.6M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 47.01
N/A
EPS
★ N/A
N/A
Revenue
$709,919,000.00
★ $771,400,000.00
Revenue This Year
$15.60
$6.89
Revenue Next Year
$18.77
$5.35
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 12.90
2.33
52 Week Low
$0.69
$3.76
52 Week High
$4.58
$8.63

Technical Indicators

Market Signals
Indicator
PLUG
MYGN
Relative Strength Index (RSI) 59.84 50.25
Support Level $1.43 $4.24
Resistance Level $2.49 $5.69
Average True Range (ATR) 0.15 0.30
MACD 0.00 0.02
Stochastic Oscillator 88.24 64.71

Price Performance

Historical Comparison
PLUG
MYGN

About PLUG Plug Power Inc.

Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: